Company profile for Adrestia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells Many of the most challenging medical problems facing us today, such as cardiovascular disease, dementia and other neurological conditions, cancer and many genetic disorders, are caused by faulty molecular pathways that lead to cellular dysfunction or death. We are searching for novel t...
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells Many of the most challenging medical problems facing us today, such as cardiovascular disease, dementia and other neurological conditions, cancer and many genetic disorders, are caused by faulty molecular pathways that lead to cellular dysfunction or death. We are searching for novel therapies that suppress or over-ride these harmful pathways and keep cells healthy. It’s a concept known as synthetic viability. Adrestia is developing therapeutics that work in an entirely new way.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Moneta Building 280 Babraham Research Campus Babraham, Cambridge CB22 3AT
Telephone
Telephone
01223 804142
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20230616268448/en

BUSINESSWIRE
16 Jun 2023

https://www.businesswire.com/news/home/20230208005076/en

BUSINESSWIRE
08 Feb 2023

https://www.businesswire.com/news/home/20221025005119/en

BUSINESSWIRE
25 Oct 2022

https://www.globenewswire.com/news-release/2022/10/25/2540748/0/en/Proteros-and-Adrestia-initiate-multi-target-partnership-to-discover-first-in-class-drugs-for-intractable-genetic-diseases.html

GLOBENEWSWIRE
25 Oct 2022

https://www.businesswire.com/news/home/20220928005044/en

BUSINESSWIRE
29 Sep 2022

https://www.businesswire.com/news/home/20220518005013/en

BUSINESSWIRE
18 May 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty